PepEvolutionDihexa
A potent synaptogenic compound in animals with zero human trials, and an HGF/c-Met mechanism that carries a real proliferation concern.
Verdict, D · Speculative
A mechanistically interesting compound with real preclinical signal but essentially no human evidence, and a c-Met/HGF mechanism that raises a legitimate proliferation question. Speculative, high caution, and not appropriate for casual experimentation.
Overview
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an angiotensin-IV-derived small molecule that acts as an HGF/c-Met potentiator, producing striking synaptogenesis in preclinical neurodegeneration models. The hype around it far outruns the data: there are no published human trials, so its efficacy and, critically, its long-term safety in people are unknown. The same HGF/c-Met pathway that drives synapse formation is also implicated in tumour growth, making the absence of human safety data a genuine, not theoretical, concern.
PepScore Breakdown, the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version?, our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI, see methodology.
Want a clinical path?
Talk to a licensed provider about Dihexa and whether it's appropriate for your situation.
Talk to a Provider ↗Telehealth. Not medical advice, for educational purposes.
Get the PepEvolution Dispatch
Monthly COA findings, vendor changes, and new grades. Research/educational only, no spam.
Educational only, not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links, this never affects grades. Consult a licensed healthcare provider before using any compound.